trivalent inactivated influenza vaccine (Mahidol University)

The influenza vaccine associated with Mahidol University, particularly in the context of the Enhance Study (NCT04151290), is an egg-derived, inactivated trivalent influenza vaccine (TIV). It contains surface antigens from three seasonal influenza virus strains, typically including two Influenza A subtypes (H1N1 and H3N2) and one Influenza B lineage. The vaccine is designed to provide active immunization by inducing the production of neutralizing antibodies that target the viral hemagglutinin protein, thereby preventing viral entry and infection. Mahidol University has conducted clinical research to evaluate optimized dosing strategies for this vaccine—such as double-dose or booster-dose regimens—specifically aimed at improving immunogenicity and clinical protection in immunocompromised populations, including patients with chronic kidney disease undergoing hemodialysis.

Other names

Egg-derived standard dose trivalent influenza vaccineTIVinfluenza vaccine-Mahidol University-influenza